SIGA to Host Business Update Call on November 6, 2025 Following Release of Third-Quarter 2025 Results

SIGA Technologies, Inc. (Nasdaq: SIGA), a prominent commercial-stage pharmaceutical company, is set to host a business update call on November 6, 2025, at 4:30 P.M. ET, following the release of its third-quarter results. This event will feature insights from Diem Nguyen, the company's Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. The call aims to provide shareholders and investors with timely updates on financial performance and strategic developments within the company.

Participants can join the call via a live webcast on SIGA’s official website, specifically within the Investor Relations section, recommending logging in 5-10 minutes before the commencement. For those wishing to attend by phone, domestic callers can connect through 1-800-717-1738, while international callers can reach the conference through 1-646-307-1865. A replay will be accessible for two weeks post-call using specific dialing instructions and the designated Conference ID: 1141989.

SIGA Technologies is at the forefront of global health, predominantly focusing on developing innovative therapies for infectious diseases, especially those caused by orthopoxviruses. Through strategic partnerships with governmental bodies and public health organizations, SIGA aims to mitigate severe health threats worldwide. The company’s leading product, TPOXX® (tecovirimat), is an antiviral medication that's already approved in the U.S. and Canada for smallpox treatment, with authorizations in Europe, the UK, and Japan for smallpox, monkeypox, cowpox, and vaccinia-related complications.

For ongoing updates and detailed information about SIGA and its initiatives, stakeholders can visit their website at www.siga.com.

As SIGA Technologies (NASDAQ: SIGA) prepares to host its business update call on November 6, 2025, investors should closely monitor several key factors that could influence the company’s stock performance after the release of their third-quarter results.

Firstly, SIGA's position as a leader in the development of antiviral treatments for infectious diseases, particularly concerning orthopoxviruses, offers significant growth potential. Given the escalating concerns over global health security, driven by pandemics and bioterrorism threats, the demand for SIGA's products, especially TPOXX® (tecovirimat), continues to grow. It would be prudent to analyze any updates or new contracts announced during the call that could showcase their expanding market presence or partnerships with governments and health agencies.

Furthermore, investor attention should focus on the financial metrics from the third quarter. Key performance indicators such as revenue growth, profit margins, and research and development expenses could provide insights into SIGA's operational efficiency and financial health. Additionally, any guidance provided for future sales figures or upcoming product launches will likely affect stock sentiment.

Another aspect to consider is the competitive landscape. SIGA operates in a niche market where competition could affect pricing power and market share. Monitoring any commentary from management regarding competition or new entrants would be informative.

Lastly, the overall market environment, particularly regarding healthcare investments, remains vital. Investors should assess external factors like regulatory changes, public health policies, and overall market sentiment towards biotech stocks.

In summary, keeping an eye on the financial performance, strategic partnerships, competitive landscape, and market conditions during SIGA's update call will be essential for making informed investment decisions. Investors are advised to log in early for the webcast to capture any early insights directly from the management team.